NRXP NRXP
Company Profile ↓Company Overview
NRXP (NRXP) is a publicly traded company listed on with a market capitalization of $97.11M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Return on capital employed stands at 103.8%.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +12.32% |
| 6 Months: | +49.75% |
| 3 Months: | +0.49% |
| 1 Month: | -26.56% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)33.01 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 103.8%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 33.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 0 | 0 | 242.00K | 983.00K | 1.07M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 97.00K | 408.00K | 631.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 145.00K | 575.00K | 437.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.75M | 3.73M | 4.17M | 5.20M | 5.18M |
| Operating Income | -134.48K | -192.37K | -271.81K | -220.24K | -163.18K | -175.74K | -183.31K | -119.30K | 104.82K | -5.15M | -25.61M | -17.12M | -20.10M | -15.71M | -9.60M | -9.14M | -3.85M | -8.19M | -5.81M | -6.00M | -7.05M | -3.02M | - | -3.75M | -3.73M | -4.02M | -4.62M | -4.75M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.51M | -17.58M | -5.85M | 1.13M | -1.03M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 671.00K | 233.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.51M | -17.58M | -5.89M | 360.00K | -1.43M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -105.03K | 15.48K | -6.60K | 28.08K | 187.97K | 176.02K | 59.20K | -1.59M | 102.29K | -5.16M | -25.49M | -117.00K | -37.05M | -13.45M | -6.98M | -9.08M | -5.51M | -8.72M | -6.06M | -6.53M | -7.90M | -1.62M | - | -5.51M | -17.58M | -5.89M | 360.00K | -1.43M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.15 | -0.71 | -0.41 | -0.72 | -0.21 | -0.11 | -0.14 | -1.66 | -0.12 | -0.07 | -0.74 | - | - | - | -0.34 | -0.98 | -0.27 | - | -0.04 |
| R&D Expense | - | - | - | - | - | - | - | - | 1.39M | 4.33M | 2.91M | 4.66M | 6.28M | 5.48M | 2.96M | 4.13M | 804.00K | 3.87M | 3.31M | 1.75M | 2.80M | 611.00K | - | 804.00K | 987.00K | 1.43M | - | 1.31M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 1.23M |
| Cost of Revenue | - | - | - | - | - | - | 0 | 505.00K |
| Gross Profit | - | - | - | - | - | - | 0 | 720.00K |
| Operating Expenses | - | - | - | - | 44.34M | 27.59M | 18.50M | 16.94M |
| Operating Income | -1.01M | -713.19K | -51.39M | - | -44.34M | -27.59M | -18.50M | -16.22M |
| EBITDA | - | - | - | - | -39.75M | -30.02M | -24.89M | -27.81M |
| Interest Expense | - | - | - | - | 0 | 120.00K | 230.00K | 671.00K |
| Pretax Income | - | - | - | - | -39.75M | -30.15M | -25.13M | -28.62M |
| Tax Provision | - | - | - | 0 | 0 | - | - | - |
| Net Income | 66.10K | 408.43K | -51.78M | - | -39.75M | -30.15M | -25.13M | -28.62M |
| Diluted EPS | - | - | -1.51 | - | -6.10 | -3.98 | -2.36 | -1.34 |
| R&D Expense | - | - | 10.62M | 20.26M | 17.03M | 13.37M | 6.20M | 3.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 69.57M | 70.80M | 32.07M | 2.94M | - | 25.82M | 7.32M | 3.65M | 12.96M |
| Current Assets | - | - | - | - | - | - | 25.80M | 6.88M | 3.30M | 8.89M |
| Cash & Equivalents | - | - | - | - | - | - | 20.05M | 4.59M | 1.44M | 7.80M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 0 | - | - | 0 | 161.00K |
| Total Liabilities | - | 93.17K | 1.26M | 2.57M | 46.71M | - | 18.41M | 19.05M | 26.87M | 28.89M |
| Current Liabilities | - | 93.17K | 567.41K | 622.44K | 46.16M | - | 15.59M | 19.05M | 21.86M | 28.58M |
| Long Term Debt | - | - | - | - | - | - | 2.82M | - | 5.01M | - |
| Total Debt | - | - | - | - | - | - | 10.53M | 9.16M | 6.58M | 631.00K |
| Total Equity | 0 | 5.00M | 5.00M | -4.84M | -43.77M | - | 7.41M | -11.73M | -23.22M | -15.94M |
| Shares Outstanding | - | - | - | - | - | - | 6.64M | 8.39M | 14.59M | 31.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -473.19K | -792.73K | -2.27M | - | -39.76M | -21.66M | -10.64M | -14.11M |
| Investing Cash Flow | -647.39K | 40.25M | -2.00K | - | -10.00K | -3.00K | 0 | -2.81M |
| Financing Cash Flow | 682.50K | -39.46M | 3.25M | - | 32.21M | 6.20M | 7.49M | 23.28M |
| Capital Expenditure | - | - | - | -7.00K | -10.00K | -3.00K | - | - |
| Free Cash Flow | - | - | - | - | -39.77M | -21.66M | -10.64M | -14.11M |
| Net Change in Cash | - | - | - | - | -7.55M | -15.46M | -3.15M | 6.35M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 58.8% |
| Operating Margin % | - | - | - | - | - | - | - | -1,324.4% |
| Net Margin % | - | - | - | - | - | - | - | -2,336.5% |
| ROE % | 1.3% | -8.4% | 118.3% | - | -536.6% | 257.0% | 108.2% | 179.6% |
| ROCE % | -1.4% | -2.3% | 118.9% | - | -433.3% | 235.1% | 101.6% | 103.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NRXP
Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPaU5kMUt0QWhmM3I1azVFWVhCbVNOZEVqbXotTHdlblJteFlxcmlkcmxHVHp2clZzdVA2SldNVzZhbklWdmVWcmV0UzVLTWRQc1Y4aXZldDJRM2tCbjJmVFFHN19WTTRTSTFnQWl3SGgxeEh0eGtMclpoTFRkbDZhZVZnMllSR1lRTklseV…
FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions - TradingView
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPLWZMbFlKcTd5N3lCNTRmYmt4T043OGxINGdIdjVvQm1lZDAybENuTkx3Rnd6Q0JTd1NPUS1iNzlDY0dTTGVaZ19uWVNrVURybDlVWlp0eHNIOXJBNDBwbHItQnNnSnMzaGpSc2p6LVNDV19qVzJuVG9COHhHX2JwUnc0S2hsSTNxY1FQMz…
HOPE starts first FDA-cleared TMS treatments in Florida clinics - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOb09GYm41SmhGaW9nX3FKXzVtU3VFZWZzb0NDTXZYcVA2N3ZGVFlGanBYeGVFdUZsazE4ZFR1RGN1QWpYbk1IS0txSmpaWUQzZV94MkN1Y1pKRXhRRlJYQ3NBSkM0RW4tbjN3VVd0b2I3c0Z1cmgzcXJxMU4wX1MxZTdJNEgxbkdHOFgwcl…
NRX Pharmaceuticals Inc (NRXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE1XN05MUGg5LVJVWkYyZ2s2YXRkX0J6LW9VbHpJYkl1bjE5RkhtekNVaFJENkxCVFREbjlQSXZDZ190R3ctbjFGb3hHVVpzSlFtM3ZFQU5HRXRBVkJlVjJ2NHhrOThmSlA1dU5sbzBQQXI?oc=5" target="_blank">NRX Pharmaceutic…
NRx Pharmaceuticals Prices Public Offering of Common Stock to Raise Approximately $20 Million | NRXP Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNNlFGWWQ4VXRMaWtlNENmTUhTQ0hILXREZUs5bUVvVUNqTER0UmxZcFA0QWRzZWkwQjNsLXc2blY4X0ZkUW5mS0d4bVlDdEdvaWVRbGlOV1IyX2JfTlJ6VFpxb2JnSFk2M2VBdmNQcnZ5QjZIdFNBY2tMSER3UE9MTWtSV3VwOWR2ZWFLQ0…
FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPbnV6ZmFFNjk3bnRaU3J2dHRPTHRhbE1VNjBhOE1KeXhJRG9CTVZwLU5fejNVR0dPbkpodFRhNEdmWW1qLVBRcWFUYVl3Mk5aclEzNTgzU0hvSHpKblpISGx5WUdrXzFzMjdwOUlmbXNLX3ljcUw4YjU2NW5paGtvcUVNTWZDVk9TbEdjNm…
NRXP — Frequently Asked Questions
What is the current share price of NRXP?
As of 2026-08-05 17:25 PDT, NRXP trades at $3.06 on NASDAQ/NYSE. Its 52-week range is $1.68 to $4.62.
What is the market capitalisation of NRXP?
NRXP has a market capitalisation of $97.11M on NASDAQ/NYSE.
What is the P/E ratio of NRXP?
NRXP trades at a trailing price-to-earnings (P/E) ratio of -2.28. Its price-to-book (P/B) ratio is -6.09.
Is NRXP a good stock to buy?
This page provides a data-driven analysis of NRXP, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.